Catalyst

Slingshot members are tracking this event:

AbbVie's HUMIRA (adalimumab) Receives CHMP Positive Opinion to Treat Certain Forms of Non-Infectious Uveitis, a Disease that Can Severely Impact Vision

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
Importance
High Medium Low
Impact on Stocks
ABBV Community voting in process
Slingshot Insights Explained
Catalyst Date
Occurred on:
May 27, 2016
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Humira, Adalimumab, Chmp Positive Opinion, Non-infectious Uveitis, Visual Acuity, Corticosteroid